UPDATE: Auxilium Pharma Reports Wider-Than-Expected Q2 Loss

Auxilium Pharmaceuticals AUXL reported a wider-than-expected loss for the second quarter. The Chesterbrook, Pennsylvania-based company posted a quarterly loss of $36.5 million, or $0.73 per share, versus a year-ago net profit of $42.7 million, or $0.86 per share. Excluding items, it lost $21.8 million, or $0.44 per share. Its total revenue dropped 17.4% to $83 million from $100.5 million. However, analysts were estimating a loss of $0.21 per share on revenue of $88.52 million. XIAFLEX US net revenue surged 75% y/y to $26.3 million, while STENDRA US net revenue rose to $6.1 million in the quarter. However, TESTOPEL US net revenue declined to $4.2 million, while Testim franchise revenue shrank to $25.2 million in the quarter. R&D spending dropped to $10.6 million from $12.9 million, while selling, general and administrative costs rose to $58.9 million from $50.7 million. "Through the second quarter of this year, we are encouraged and pleased with the launches of XIAFLEX® for Peyronie's disease and STENDRA® for erectile dysfunction We believe these products offer patients important new treatment options and represent growth opportunities for Auxilium," said Adrian Adams, Chief Executive Officer and President of Auxilium. Auxilium shares gained 2.55% to close at $19.83 yesterday.